Discover
GPCR
Structure Therapeutics Inc.
52.12
2 x 38.52
2 x 65.83
bid
ask
-
1.55
2.89%
2 @ 04:10 AM
52.17 +0.05 (0.10%)
| Ytd | -25.06% | |
| 1y | 154.12% |
51.25
day range
54.66
15.80
52 week range
94.90
| Open | 53.93 | Prev Close | 53.67 | Low | 51.25 | High | 54.66 | Mkt Cap | 3.70B |
| Vol | 1.64M | Avg Vol | 869.99K | EPS | -2.64 | P/E | N/A | Forward P/E | -26.96 |
| Beta | -1.42 | Short Ratio | 8.04 | Inst. Own | 96.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 42.16 | 200-d Avg | 49.35 | 1yr Est | 104.59 |
GPCR News
benzinga.com
Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model
As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and s
benzinga.com
Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ra
benzinga.com
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70
HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
Structure Therapeutics Publishes Phase 2b Aleniglipron Results In Nature Medicine, Reporting Up To 1
Aleniglipron is an oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) in develo